secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quantum Genesis AI Corp. (QTZM)
CIK:        0001663038
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001477932-26-002252
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quantum Genesis AI confirms CEO assignment of ibuprofen synthesis patent
------------------------------------------------------------------------

- CEO Naveen Kulkarni assigned all rights in US Patent App. US20250146029A1 for enzymatic ibuprofen synthesis to the company.
- Assignment effective as of Nov. 2, 2023, formalizing a prior 2023 Asset Purchase Agreement.
- Company will amend FY2025 10-K and FY2026 Q1 & Q2 10-Qs to update IP disclosures.
- No new consideration; agreement confirms existing ownership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1663038/000147793226002252/0001477932-26-002252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1663038/000147793226002252/qtzm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-002252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer